BofA lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $17 from $20 and keeps a Buy rating on the shares. The firm estimates approximately 25-35 new patients added per month in Q1 and assuming a flat growth rate of patients over the quarter sees about 18 new patient starts per month in Q2, which it calls out as “significantly less than the lower end of our estimate in 1Q.” The new FY25 guidance of $140M-$150M net product revenue “seems to reflect a slowdown in growth,” which will be something to watch as Day One focuses on improving both breadth and depth of prescriber adoption, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One price target lowered to $25 from $36 at H.C. Wainwright
- Day One Biopharma Reports Strong Q2 2025 Growth
- Day One Biopharmaceuticals Reports Strong Q2 2025 Results
- Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c)
- Day One Biopharmaceuticals appoints Michael Vasconcelles as Head of R&D